Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06089083 · ClinicalTrials.gov registry record

PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

A clinical trial of Gynecologic Cancer and Malignant Female Reproductive System Neoplasm, sponsored by University of California, San Francisco.

Recruiting
Registry status
500
Enrollment target
2
Study locations

NCT06089083: Recruiting study of Gynecologic Cancer and Malignant Female Reproductive System Neoplasm, sponsored by University of California, San Francisco.

NCT06089083 is a study of Gynecologic Cancer and Malignant Female Reproductive System Neoplasm that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 500 participants, below the 755-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (34% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06089083, a study of Gynecologic Cancer and Malignant Female Reproductive System Neoplasm, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
500 participants
Enrollment target
2
Study locations

Study Summary

This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.

Primary Outcome

The Fried frailty phenotype (FP) assesses physical frailty through five criteria: unintentional weight loss; weakness or poor handgrip strength; self-reported exhaustion; slow walking speed; and low physical activity. Participants who receive a score of \>3 will be categorized as 'frail'. Participants who receive a score \<=3 will be categorized as Non-frail at time of enrollment.

Interventions

  • OTHER Physical function assessment
  • OTHER Self-reported Assessments and Questionnaires
  • PROCEDURE Surgery (Standard of Care, Non-Interventional)

Study Locations (2)

California

  • University of California, San Francisco - San Francisco

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2023-10-18
Est. Completion 2033-11-30

What NCT06089083 shows while recruiting

NCT06089083 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 755-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (34% lower).

The record links to 3 conditions, with Gynecologic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Physical function assessment is the first listed.

NCT06089083 reports a single indexed study location in California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06089083 about?

NCT06089083 is a clinical study titled "PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery". This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.

What is the current status of trial NCT06089083?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-10-18. Estimated completion is 2033-11-30.

What conditions does trial NCT06089083 study?

This clinical trial studies the following conditions: Gynecologic Cancer, Malignant Female Reproductive System Neoplasm, Gynecologic Neoplasm.

What interventions are being tested in trial NCT06089083?

The interventions under investigation include: Physical function assessment (OTHER), Self-reported Assessments and Questionnaires (OTHER), Surgery (Standard of Care, Non-Interventional) (PROCEDURE).

Who is sponsoring clinical trial NCT06089083?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06089083 being conducted?

This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gynecologic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06089083's enrollment target sits among peer trials

500 7th of 55 higher than 49 of 55 other Gynecologic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06089083, the US trial registry maintained by the National Library of Medicine. NCT06089083 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.